Background Type 2 diabetes is associated with early development of endothelial
dysfunction. Patients present with typical dyslipidemia (predominantly high levels of …

The goal was to investigate the effect of micronized fenofibrate, a hypolipidemic drug, on
inflammatory markers and proinsulin in patients with type 2 diabetes who had …

Fenofibrate is a fibric acid derivative with lipid-modifying effects that are mediated by the
activation of peroxisome proliferator-activated receptor-α. Fenofibrate also has a number of …

Objective Dislipidaemia in type 2 diabetes mellitus contributes to arterial endothelial
dysfunction and an increased risk of cardiovascular disease. Fenofibrate, a lipid-regulating …

Objective: To evaluate the efficacy of fenofibrate, simvastatin or their combination in type 2
diabetic patients with combined dyslipidaemia. Research design and methods: 241 patients …

Background Fenofibrate offers a number of benefits on the cardiovascular system and it is
plausible that its anti-inflammatory, anti-oxidant and anti-fibrotic effects and enhancement of …

Dyslipidaemia contributes to endothelial dysfunction and CVD (cardiovascular disease) in
Type 2 diabetes mellitus. While statin therapy reduces CVD in these patients, residual risk …

This study evaluated the postprandial (PP) response to an oral fat load in 28 male patients
with type 2 diabetes (mean HbA1c of 5.1%), all receiving metformin and performing physical …

Aims/hypothesis In the double-blind placebo-controlled Fenofibrate Intervention and Event
Lowering in Diabetes trial (n= 9,795), fenofibrate reduced major cardiovascular events in …

Background: Fasting and post‐prandial hypertriglyceridemia have been associated with
endothelial dysfunction. Objective: To investigate the effects of a 3‐month treatment with …